Threshold for genetic testing in women with breast cancer needs to be determined

BRCA1 carriers with high grade triple negative cancers are known to do better with aggressive treatment. 5 Additionally, if the threshold for genetic testing is lowered, we may not have sufficient resources to provide complex reconstructions.Knowledge of mutation status undoubtedly affects subsequen...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMJ (Online) 2014-03, Vol.348 (mar05 4), p.g1863-g1863
Hauptverfasser:	Basu, Narendra Nath, Barr, Lester, Evans, D Gareth, Ross, Gary L
Format:	Artikel
Sprache:	eng
Schlagworte:	BRCA1 Protein - genetics BRCA2 Protein - genetics Breast cancer Breast Neoplasms - surgery Cancer therapies CONTRALATERAL MASTECTOMY AND BRCA1 AND BRCA2 DNA, Neoplasm - genetics Female Forecasting Genetic screening Genetic testing Humans Mastectomy Mastectomy - methods Mutation Surgery
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	BRCA1 carriers with high grade triple negative cancers are known to do better with aggressive treatment. 5 Additionally, if the threshold for genetic testing is lowered, we may not have sufficient resources to provide complex reconstructions.Knowledge of mutation status undoubtedly affects subsequent treatments, including adjuvant or neoadjuvant treatment and reconstructive options, but the threshold for genetic testing must be clearly determined.
ISSN:	0959-8138 1756-1833 1756-1833
DOI:	10.1136/bmj.g1863